CoChat

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study

Open access
Richtig, Georg, Hoeller, Christoph, Wolf, Martin, Wolf, Ingrid, Rainer, Barbara M., Schulter, Günter, Richtig, Markus, Grübler, Martin R., Gappmayer, Anna, Haidn, Thomas, Kofler, Julian, Huegel, Rainer, Lange-Asschenfeldt, Bernhard, Pichler, Martin, Pilz, Stefan, Heinemann, Akos, Richtig, Erika · 2018 · PLOS ONE
Cited by 112

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Immunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting patients at risk of severe side effects. METHODS: In this retrospective analysis, we investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma. Patients with metastatic melanoma who received a monotherapy of up to 4 doses of ipilimumab (3 mg/kg) every 3 weeks from 2011 to 2014 in three major hospitals in Austria were included. Patients were classified into two groups: normal group (BMI<25) and overweight group (BMI≥25). RESULTS: 40 patients had a normal BMI, and 36 had a BMI above normal. Patients with a BMI that was above normal showed significantly higher response rates (p = 0.024, χ2), and lower likelihood of brain metastases (p = 0.012, χ2). No differences were found between both groups with respect to gender (p = 0.324, χ2), T-stage (p = 0.197, χ2), or the occurrence of side effects (p = 0.646, χ2). Patients with a BMI above normal showed a trend towards longer overall survival (p = 0.056, Log-Rank), but no difference was found regarding progression-free survival (p = 0.924, Log-Rank). CONCLUSIONS: The BMI correlated with the response to ipilimumab treatment in a cohort of metastatic melanoma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0204729

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 112

Metadata

Authors
Richtig, G., Hoeller, C., Wolf, M., Wolf, I., Rainer, B. M., Schulter, G., Richtig, M., Grübler, M. R., Gappmayer, A., Haidn, T., Kofler, J., Huegel, R., Lange-Asschenfeldt, B., Pichler, M., Pilz, S., Heinemann, A., & Richtig, E.
Venue
PLOS ONE
Published
2018-10-01
Volume
13
Issue
10
Pages
e0204729
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2894982998
Cited by
112
References
9
FWCI
3.79
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. https://app.cochat.ai/papers/10.1371/journal.pone.0204729
The paper
Richtig, G., Hoeller, C., Wolf, M., Wolf, I., Rainer, B. M., Schulter, G., Richtig, M., Grübler, M. R., Gappmayer, A., Haidn, T., Kofler, J., Huegel, R., Lange-Asschenfeldt, B., Pichler, M., Pilz, S., Heinemann, A., & Richtig, E. (2018). Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. PLOS ONE. https://doi.org/10.1371/journal.pone.0204729

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.